pharma · Advanced Solid Tumor · Sarcoma · PRLD
Prelude Therapeutics
Prelude Therapeutics Inc
Prelude Therapeutics is a pharma organization headquartered in Wilmington, USA. It trades on NYSE under ticker PRLD. Primary therapeutic focus areas include Advanced Solid Tumor, Sarcoma, Acute Myeloid Leukemia, Polycyth
Company details
- Status
- Public
- HQ
- 175 Innovation Boulevard, Wilmington, DE 19805, US
- Founded
- 2016
- Employees
- 111
- Programs
- 13
- Drugs
- 5
- Patents
- 16
PRT12396
Phase 1 · small molecule · Polycythemia Vera (PV)
PRT12396 for Polycythemia Vera (PV) is a Phase 1 program (small_molecule) at Prelude Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Internal code PRT12396-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Prelude Therapeutics Inc
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Polycythemia Vera (PV)
- Status
- active
- Trials
- 1